The “pharma focus” section highlights our desire to provide pain professionals with the resources and information they need to provide the best patient care. As part of this mission, we are taking a closer look at the agent Humira (adalimumab, Abbott), a subcutaneous self-injection indicated to treat patients with rheumatoid arthritis (RA).

A variety of pre-, intra-, and postoperative factors contribute to increased length of stay for patients who undergo level 1 minimally invasive transforaminal interbody fusions spine surgery, according to a study published online May 8 in Spine.

Hospira has voluntarily recalled a single lot of the injectable opioid analgesic hydromorphone hydrochloride (Dilaudid), according to a statement released by the FDA.

Ill. Doctor Gets 4 Life Terms in Drug Case

Follow the Money: Pain, Policy, and Profit

Cognitive Behavioral Therapy Aids Long-Term Pain Management

Congressional Testimony Reinforces the Mission of PAINWeek

The Centers for Medicare & Medicaid Services may eliminate your TENS Coverage